Filip Dubovsky, Novavax CMO
January 27, 2023 02:12 PM ESTUpdated 02:48 PM
Pharma
FDA+

No­vavax gets ready to take an­oth­er shot at Covid vac­cine mar­ket with next sea­son plans

Nicole DeFeudis

Editor

While mR­NA took cen­ter stage at yes­ter­day’s FDA vac­cine ad­vi­so­ry com­mit­tee meet­ing, No­vavax an­nounced its plans to de­liv­er an up­dat­ed pro­tein-based vac­cine based on new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times